Why You Should Attend:
This two day conference will enable attendees to streamline risk mitigation and improve drug safety by leveraging tools and technologies and interpreting developments in regulatory compliance. The 7thinstallment of Pharmacovigilance, Drug Safety & Risk Management will focus on improving PV strategies to enable predictive drug safety in order to increase patient safety, and decrease drug risk potential.
Develop more proficient and profound pharmacovigilance strategies to utilize throughout product lifecycle. Streamline drug safety and regulatory approval process and increase patient voluntary reporting.
Key Speakers:
Anders Lindholm MD, PhD
Vice President, Head of Drug Safety Inflammation & Immunology
Celgene Corporation
Mariette Boerstoel
Senior Vice President, Head Global Drug Safety
Shire
John Price, MD PhD
Vice President, Global Pharmacovigilance and Drug Safety
Alexion Pharmaceuticals, Inc
Stephen Klincewicz
Vice President Pharmacovigilance
Sorrento Therapeutic
Alexandre Kiazand, M.D.
Head Safety Science
AstraZeneca
Key Topics:
- Identify trends in pharmacovigilance to establish predictive drug safety methods
- Examine existing compliance framework to assess potential impacts of forthcoming regulations affecting
- Incorporate pharmacovigilance throughout product lifecycle, from clinical development to patient care in order to improve drug safety
- Leverage tools and technology to enhance pharmacovigilance strategy integration
- Interpret & utilize real world evidence for optimized signal management
Comments